Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Alliance Pharma PLC Ord 1P (APH)

Related News

31-Jul-2017 09:00 AM

Broker Forecast - finnCap issues a broker note on Alliance Pharma PLC

finnCap today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and cut its price target to 58p (from 65p). Story provided by
25-May-2017 09:41 AM

Alliance Pharma cash flow remains strong

Alliance Pharma's cash flow remains strong and it is on target to reduce adjusted net debt/EBITDA ratio to around 2x by the end of the year, shareholders at the annual general meeting will be told. Chairman Andrew Smith will say: "The year is p
09-May-2017 09:30 AM

Broker Forecast - finnCap issues a broker note on Alliance Pharma PLC

finnCap today initiates coverage of Alliance Pharma PLC (LON:APH) with a buy investment rating and price target of 65p. Story provided by
21-Mar-2017 09:58 AM

Alliance Pharma settlement agreement with Sinclair

Alliance Pharma has reached agreement with Sinclair Pharma for compensation in connection with the material reduction of business in Kelo-stretch, as noted in the company's results for 2015. Kelo-stretch, a dermocosmetic cream for the prevention a
02-Mar-2017 09:59 AM

Alliance Pharma schedules FY results

Alliance Pharma will announce its preliminary results for the year ended 31 December on 29 March. At 9:59am: (LON:APH) Alliance Pharma PLC share price was +0.63p at 47.38p Story provided by
23-Jan-2017 07:47 AM

Alliance revenues more than double

Alliance Pharma said it expected revenue for the year ended 31 December to be more than double the prior year at £97.5m (2015: £48.3m). It said this had been driven by the transformational acquisition of the ex-Sinclair products in December
14-Sep-2016 07:35 AM

Alliance revenues up 104%

Alliance Pharma's revenues for the six months to the end of June rose by 104% to £46.4m. It said ex-Sinclair products had made an immediate contribution to the results, in line with expectations and enabling revenues to more than double and th
19-Jul-2016 07:18 AM

Alliance's sales

Alliance Pharma (APH) said it performed well and in line with the board's expectations with sales more than doubling to £46.4m (2015: £22.8m), following the acquisition of the Sinclair Healthcare Products business in December 2015. The S
07-Apr-2016 01:23 PM

Alliance Pharma revenues up 11%

Alliance Pharma's revenues rose by 11% to GBP48.3m in the year to the end of December, including GBP0.8m from the acquisition of the Sinclair healthcare products business. Reported pre-tax profit rose by 49% to GBP15.2m and underlying pre-tax profi
18-Mar-2016 09:05 AM

Alliance Pharma schedules FY results

Alliance Pharma, the speciality pharmaceutical company, will announce its preliminary results for the year ended 31 December on 7 April. At 9:05am: (LON:APH) Alliance Pharma PLC share price was +0.13p at 52.38p Story provided by
21-Jan-2016 09:42 AM

Alliance Pharma trading profits on track

Alliance Pharma expects its trading profit before tax for the year ended 31 December to be in line with the board's forecasts. Group revenue (excluding JV sales) for 2015 is expected to be more than 10% up at GBP48.2 million, including revenues of
09-Sep-2015 08:03 AM

Alliance Pharma revenue and profits up

Speciality pharmaceutical company Alliance Pharma's revenues rose to £22.9=8m in the six months to the end of June - up from £21.4m last time. Teh group says Hydromol continues to grow well, with sales up 11% to £3.3m (H1 2014: £3.0m) while the
17-Aug-2015 09:20 AM

Alliance Pharma schedules interims

Alliance Pharma, the speciality pharmaceutical company, will announce its results for the six months to 30 June on 9 September. At 9:20am: (LON:APH) Alliance Pharma PLC share price was 0p at 58p Story provided by
13-Jul-2015 07:27 AM

Alliance Pharma on track

Alliance Pharma says it continues to perform well and in line with management's expectations, with sales of approximately £22.8m (H1 2014: £21.4m) in the first half of the year. A pre-close update says: "Our growth products continue to deli
10-Jul-2015 07:58 AM

Alliance Pharma appoints new finance director

Alliance Pharma (AIM: APH), the speciality pharmaceutical company, has announced the appointment of Andrew Franklin as finance director. He will join in September. From 2010 to 2012, Mr Franklin was finance director and company secretary of Genzyme Th
27-May-2015 07:46 AM

Alliance revenues up

Alliance Pharma's trading in the first four months of this year has been satisfactory with revenues 6% up at £15.6m, shareholders at the annual general meeting today will be told. Chairman Andrew Smith will say: "Hydromol, our biggest brand,
20-Apr-2015 09:20 AM

Alliance Pharma 'set for resumption in growth'

Hardman & Co has issued a research report on Alliance Pharma which says the company is set for a resumption in growth. The report says: "Alliance Pharma released a solid set of full year numbers, demonstrating the resilience of its underlying core b
10-Apr-2015 08:59 AM

Alliance Pharma schedules AGM

Alliance Pharma will hold its annual general meeting on 27 May. At 8:59am: (LON:APH) Alliance Pharma PLC share price was 0p at 39.75p Story provided by
25-Mar-2015 09:22 AM

Alliance pre-tax profits fall

Alliance Pharma's revenues fell to £43.5m in the year to the end of December (2013: £45.3m) and pre-tax profits dropped to £10.8m from £12.0m. The proposed final dividend of 0.667p per share is up 10% taking the total for the year to 1.000p per
17-Feb-2015 09:44 AM

Alliance Pharma FD to step down

Alliance Pharma finance director Richard Wright is to leave the company after nearly eight years in the role to pursue other opportunities. He will remain in his role until 31 May. A search process for a new FD has begun and the company will provide an
02-Feb-2015 12:24 PM

Alliance Pharma acquires MacuVision

Alliance Pharma, the speciality pharmaceutical company, has announced that its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired MacuVision Europe for initial consideration of £5.5 million plus the net asset value of MacuVision at com
26-Jan-2015 09:40 AM

Procserve CEO joins Alliance Pharma board

Alliance Pharma has appointed Nigel Clifford as an independent non-executive director with immediate effect. Clifford is chief executive of Procserve Holdings Limited, a leading company in enabling secure transactions online. He is also currently a non-
19-Jan-2015 07:33 AM

Alliance Pharma on track

Alliance Pharma expects pre-tax profits for the year ended 31 December to be in line with current market expectations. Turnover is expected to be £43.5m (2013: £45.3m after restatement following the adoption of IFRS 11). Sales of the Hydromol derma
19-Jan-2015 07:14 AM

Alliance Pharma on track

Story provided by
18-Dec-2014 03:35 PM

Alliance Pharma non-exec to step down

Alliance Pharma, the speciality pharmaceutical company, confirms that, further to the announcement on 30 December 2013, Paul Ranson will retire from his position as non-executive director on 31 December. At 3:35pm: (LON:APH) Alliance Pharma PLC share pr
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t